Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

InterCure Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK & HERZLIYA, ISRAEL, JUNE 22, 2026 (GLOBE NEWSWIRE) -- INTERCURE LTD. (NASDAQ: INCR) (TASE: INCR) (DBA CANNDOC) (INTERCURE OR THE COMPANY), TODAY ANNOUNCED THAT, FURTHER TO THE COMPANY'S PRIOR REPORTS REGARDING GROWING DEMAND IN GERMANY AND OPPORTUNITIES ARISING FROM THE RECENT U.S. FEDERAL RESCHEDULING OF CANNABIS, THE COMPANY HAS ENTERED INTO A BINDING TERM SHEET PROVIDING FOR FUNDING COMMITMENTS OF NIS 22 MILLION (APPROXIMATELY US$7.4 MILLION), WHICH MAY INCREASE TO NIS 54 MILLION (APPROXIMATELY US$18.6 MILLION) (THE PRIVATE PLACEMENT).

INTERCURE SECURES NIS 22 MILLION IN PRIVATE PLACEMENT FINANCING LED BY LEADING PHARMA-FOCUSED HEDGE FUNDS

FIRST TRANCHE CLOSING (50%) OF BOTANICO TRANSACTION EXPANDS INTERNATIONAL PLATFORM WITH EXCLUSIVE ACCESS TO U. S. GENETICS, PREMIUM BRANDS AND ADVANCED AI-DRIVEN TECHNOLOGIES; COMPANY REPORTS GROWING DEMAND IN GERMANY AND EVALUATES OPPORTUNITIES IN REGULATED U. S. MEDICAL CANNABIS MARKETS.

INTERCURE INITIATES STRATEGIC REVIEW OF U.S. MEDICAL CANNABIS OPPORTUNITIES FOLLOWING HISTORIC FEDERAL RESCHEDULING AND COMPLETES THE INITIAL CLOSING OF BOTANICO ACQUISITION

THE COMPANY REPORTED OVER NIS 270 MILLION IN REVENUE, NIS 37 MILLION IN NET LOSS, NIS 47 MILLION IN ADJUSTED EBITDA AND NIS 17 MILLION IN POSITIVE OPERATING CASH FLOW, REFLECTING STRONG RESILIENCE AND CONSISTENT PROFITABILITY, WITH A TWELFTH CONSECUTIVE HALF-YEAR OF POSITIVE ADJUSTED EBITDA, AS THE COMPANY CONTINUES TO RECOVER FROM THE IMPACT OF THE OCTOBER 7, 2023 EVENTS NEW YORK AND HERZLIYA, ISRAEL, APRIL 30, 2026 (GLOBE NEWSWIRE) -- INTERCURE LTD.

INTERCURE ANNOUNCES 2025 RESULTS WITH NIS 270 MILLION IN REVENUE AND POSITIVE OPERATING CASH FLOW

NEW YORK AND HERZLIYA, ISRAEL, MARCH 03, 2026 (GLOBE NEWSWIRE) -- INTERCURE LTD. (NASDAQ: INCR) (TASE: INCR) (INTERCURE OR THE COMPANY) TODAY ANNOUNCED THAT ON FEBRUARY 25, 2026 THE COMPANY RECEIVED A WRITTEN NOTICE (THE NOTICE) FROM THE NASDAQ STOCK MARKET LLC INDICATING THAT THE COMPANY WAS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE 5450(A)(2), AS THE COMPANY'S CLOSING BID PRICE FOR ITS ORDINARY SHARES, OR ORDINARY SHARES, WAS BELOW $1.00 PER SHARE FOR THE LAST 30 CONSECUTIVE BUSINESS DAYS.

INTERCURE RECEIVES NASDAQ NOTIFICATION REGARDING MINIMUM BID REQUIREMENT

INTERCURE REPORTS PRELIMINARY ESTIMATED REVENUE OF NIS 265 MILLION FOR 2025 AND POSITIVE ADJUSTED EBITDA, MARKING ITS TWELFTH CONSECUTIVE HALF-YEAR OF POSITIVE ADJUSTED EBITDA.

INTERCURE ANNOUNCES PRELIMINARY ESTIMATED 2025 REVENUE OF NIS 265 MILLION, POSITIVE ADJUSTED EBITDA AND CASH OF NIS 43 MILLION

INTERCURE REPORTS PRELIMINARY ESTIMATED REVENUE OF NIS 265 MILLION FOR 2025 AND POSITIVE ADJUSTED EBITDA2, MARKING ITS TWELFTH CONSECUTIVE HALF-YEAR OF POSITIVE ADJUSTED EBITDA. REVENUE FOR 2025 REPRESENTS AN INCREASE OF APPROXIMATELY 11% COMPARED TO 2024, WHILE REVENUE FOR THE SECOND HALF OF 2025 IS NEARLY 20% HIGHER THAN THE CORRESPONDING PERIOD IN THE PRIOR YEAR.

INTERCURE ANNOUNCES PRELIMINARY ESTIMATED 2025 REVENUE OF NIS 265 MILLION, POSITIVE ADJUSTED EBITDAAND CASH OF NIS 43 MILLION

AGREEMENTS FORMALIZE RESEARCH PARTNERSHIP COMBINING INTERCURE'S GLOBAL PHARMACEUTICAL PLATFORM WITH CANNASOUL'S WORLD-CLASS ANALYTICS AND SCIENTIFIC INNOVATION

INTERCURE AND CANNASOUL SIGN STRATEGIC INVESTMENT AND COLLABORATION AGREEMENTS TO ADVANCE CANNABIS SCIENCE AND PHARMACEUTICAL INNOVATION

THE COMPANY REPORTS NIS 130 MILLION IN REVENUE AND NIS 12 MILLION IN POSITIVE OPERATING CASH FLOW, DEMONSTRATING RESILIENCE AND SUSTAINED PROFITABILITY WITH ITS ELEVENTH CONSECUTIVE HALF OF POSITIVE ADJUSTED EBITDA AMIDST ONGOING RECOVERY IN ISRAEL

INTERCURE REPORTS FIRST HALF 2025 RESULTS WITH NIS 130 MILLION IN REVENUE AND POSITIVE OPERATING CASH FLOW

ACQUISITION OF LEADING CANNABIS COMPANY MARKS MAJOR MILESTONE IN INTERCURE'S COMMERCIAL EXPANSION STRATEGY, BRINGING ACCESS TO PREMIUM AMERICAN BRANDS AND STATE-OF-THE-ART CULTIVATION TECHNOLOGIES

InterCure Ltd.

INCR

Price

Financial Reports

No items found.

Press Releases

InterCure Ltd.

INCR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

INCR